Top of this page
Skip navigation, go straight to the content
Scroll down to discover UCB
Zilucoplan (RA101495)
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Lay summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Paroxysmal Nocturnal Hemoglobinuria | Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study |
RA101495-01.202 Ongoing |
|||||
| Paroxysmal Nocturnal Hemoglobinuria | Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients |
RA101495-01.201 Completed |
LINK |
||||
| Paroxysmal Nocturnal Hemoglobinuria | Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab |
RA101495-01.203 Completed |
|
||||
| Generalized Myasthenia Gravis | Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis |
RA101495-02.201 Completed |
|
Howard J.F., JAMA neurology 2020; 77(5):582–92 | |||
| Immune-Mediated Necrotizing Myopathy | Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy |
RA101495-02.202 Ongoing |
|
||||
| Generalized Myasthenia Gravis | Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE) |
RA101495-02.301 Ongoing |
|||||
| Generalized Myasthenia Gravis | Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT) |
RA101495-02.302 Ongoing |
|